Compositional and functional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia: A systematic review [version 1; peer review: 2 approved]

Nuala Murray¹, Sukainah Al Khalaf²,³, David Kaulmann², Edgar Lonergan⁴, John F Cryan⁵, Gerard Clarke¹,⁶, Ali Khashan²,³, Karen O'Connor¹,⁴

¹Department of Psychiatry and Neurobehavioural Science, University College Cork, Cork, T12XF62, Ireland
²School of Public Health, University College Cork, Cork, T12XF62, Ireland
³INFANT Research Centre, University College Cork, Cork, T12XF62, Ireland
⁴RISE, Early Intervention in Psychosis Service, South Lee Mental Health Services, Cork, Ireland
⁵Department of Anatomy and Neuroscience, University College Cork, Cork, T12XF62, Ireland
⁶APC Microbiome Ireland, University College Cork, Western Rd, Cork, Ireland T12XF62, University College Cork, Cork, T12XF62, Ireland

First published: 29 Sep 2021, 4:108
https://doi.org/10.12688/hrbopenres.13416.1
Latest published: 29 Sep 2021, 4:108
https://doi.org/10.12688/hrbopenres.13416.1

Abstract

Background: Gut and oral microbiota are intrinsically linked to human health. Recent studies suggest a direct link with mental health through bidirectional gut–brain pathways. Emerging evidence suggests that the composition and/or function of intestinal microbiome differs in those with psychosis and schizophrenia as compared with controls. There is relatively little research on the predicted or actual functional alterations associated with the composition of oral and gut microbiota in patients with psychosis. We will perform a systematic review and meta-analysis to identify, evaluate and if possible, combine the published literature on compositional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia compared with healthy controls. We also aim to explore the potential functional impact of any compositional changes.

Methods: Original studies involving humans and animals using a case-control, cohort or cross-sectional design will be included. The electronic databases PsycINFO, EMBASE, Web of Science, PubMed/MEDLINE and Cochrane will be systematically searched. Quantitative analyses will be performed using random-effects meta-analyses to calculate mean difference with 95% confidence intervals.

Discussion: Changes in microbiota composition in psychosis and schizophrenia have been correlated with alternations in brain structure and function, altered immunity, altered metabolic pathways and symptom severity. Changes have also been identified as potential biomarkers for psychosis that might aid in diagnosis. Understanding

Open Peer Review

Reviewers Status

Invited Reviewers

1. Monty Lyman, University of Oxford, Oxford, UK
2. Belinda R. Lennox, University of Oxford, Oxford, UK
3. Melanie Focking, Royal College of Surgeons in Ireland, Dublin, Ireland

Any reports and responses or comments on the article can be found at the end of the article.
how predicted or actual functional alterations in microbial genes or metabolic pathways influence symptomatic expression and downstream clinical outcomes may contribute to the development of microbiome targeted interventions for psychosis.

**Registration:** The study is prospectively registered in PROSPERO, the International Prospective Register of Systematic Reviews (CRD42021260208).

**Keywords**
Schizophrenia, Psychosis, Microbiota, Microbial Metabolites, Inflammation, Diversity

Corresponding author: Karen O'Connor (Karen.OConnor3@hse.ie)

**Author roles:** Murray N: Data Curation, Formal Analysis, Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation; Al Khalaf S: Data Curation, Formal Analysis, Methodology, Software, Writing – Review & Editing; Kaulmann D: Conceptualization; Lonergan E: Conceptualization; Cryan JF: Conceptualization; Clarke G: Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Writing – Review & Editing; Khashan A: Data Curation, Formal Analysis, Methodology, Software, Writing – Review & Editing; O'Connor K: Conceptualization, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2021 Murray N et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Murray N, Al Khalaf S, Kaulmann D et al. Compositional and functional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia: A systematic review [version 1; peer review: 2 approved] HRB Open Research 2021, 4:108 https://doi.org/10.12688/hrbopenres.13416.1

**First published:** 29 Sep 2021, 4:108 https://doi.org/10.12688/hrbopenres.13416.1
**Introduction**

The gut microbiota is a complex ecological community of microbes which are diverse and personalized and includes bacteria, fungi and viruses. The collective microbial genome of these microorganisms is termed the microbiome and is often considered a second modifiable genome in the human body. This gastrointestinal ecosystem is intrinsically linked to human health and recent studies suggest a direct link with mental health. Gut microorganisms communicate with the brain through the gut-brain axis in a two-way communication system. This axis describes key pillar physiological systems including the endocrine, nervous, immune, and metabolic systems facilitating behavioural responses. Several processes have been investigated as mechanisms underpinning communication along this axis, including tryptophan metabolism, the hypothalamic-pituitary-adrenal axis, the production of microbial metabolites such as short chain fatty acids and the vagus nerve. A healthy microbiome supports effective signalling along these bidirectional gut–brain pathways. These pathways may impact on a broad range of neurological and psychiatric conditions. Compositional and functional microbiome alterations have been associated with central nervous system (CNS) disorders including depression, Parkinson’s disease, autistic spectrum disorder, and attention deficit hyperactivity disorder. Emerging evidence suggests that the composition and/or function of intestinal microbiome differs in those with schizophrenia as compared with controls.

Psychosis is a condition that affects the way the brain processes information. When experiencing psychosis people can become disconnected from reality and experience hallucinations and delusions. They can experience social withdrawal, anhedonia, and struggle to motivate themselves. Impaired cognition is also a typical symptom of acute psychosis. Psychosis is associated with an array of mental illnesses including schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder and depression. Psychotic symptoms can also be drug induced.

The aetiology of psychosis is thought to be multifactorial and the result of interactions between genetic and environmental factors. Several theories have attempted to explain its pathogenesis and alterations in neurotransmitter pathways involving dopamine, glutamate, and γ-aminobutyric acid (GABA) have been implicated. Converging evidence suggests that psychosis is associated with chronic systemic and gastrointestinal inflammation, oxidative stress, and metabolic dysfunction. Metabolic and gut disturbances are highly prevalent in psychosis and schizophrenia, with comorbidities including celiac disease, colitis, and irritable bowel syndrome. In fact, gastrointestinal diseases are the third leading cause of natural deaths in schizophrenia. Physiological dysfunctions implicated in psychosis such as inflammation and oxidative stress may be associated with changes in the microbiome.

Whilst empirical investigations have focused on elucidating compositional and functional aspects of the intestinal microbiota in maintaining ongoing physiological processes within the gastrointestinal tract, there is relatively little research on the predicted or actual functional alterations associated with the composition of oral and gut microbiota in patients with psychosis. Multiple studies have documented an interaction between the gut microbiome and immunity, cognitive functioning, and behaviour in animal models. For example, findings from mechanistic studies in rodent models demonstrate that compositional alterations during early neurodevelopment or in adulthood can lead to direct CNS effects that manifest during adulthood. Translational support from clinical populations that reflect endophenotypes characteristic of schizophrenia is more difficult to obtain. We will perform a systematic review and meta-analysis to identify, evaluate and if possible, combine data on the compositional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia. We also aim to explore mechanistic insights and/or the evidence for a potential causal role and in both human and animal models.

**Objectives**

1. To systematically review previous studies that have investigated the association between psychosis or schizophrenia and compositional and functional alterations in the oral and gut microbiota.
2. To undertake a meta-analysis of compositional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia.
3. To systematically review the data on the clinical and functional consequences of these alterations in humans and animals, from a causal and mechanistic perspective.

**Methods**

The protocol for this systematic review was registered on PROSPERO the international prospective register of systematic reviews (CRD42021260208). This systematic review and meta-analysis will be conducted in accordance with the guidelines for systematic review and meta-Analysis (PRISMA) and protocols (PRISMA-P) (online supplemental appendix 1).

**Eligibility criteria**

The systematic review will include original studies using a case-control, cohort or cross-sectional design. Case reports, expert opinions, and reviews will not be eligible for inclusion. Clinical studies will include human adults. Preclinical studies will focus on animal studies involving the faecal microbiota transplant of psychosis-associated microbiota consortia.

**Information sources and search strategy**

The electronic databases PsycINFO, EMBASE, Web of Science, PubMed/MEDLINE and Cochrane will be systematically searched. Peer-reviewed research articles from 1990–2021 will be considered, so that current literature is evaluated. The search terms will include both free text and MeSH terms. Our search strategy for PubMed/MEDLINE is as follows:

1. (‘microbiota’ OR ‘microflora’ OR ‘microbiome’ OR ‘bacterial microbiome’ OR ‘intestine mucosa’ OR ‘gut brain’ OR ‘oral microbiota’ OR ‘oral microbiome’ OR ‘oral microflora’ OR ‘RNA 16S’ OR ‘gut microbiota’ OR ‘gut microbiome’ OR ‘RNA 16S’ OR ‘oral microbiome’ OR ‘oral microbiota’ OR ‘oral microflora’ OR ‘microflora’ OR ‘microbiome’ OR ‘bacteria’)

   **Note:** The search strategy includes synonyms and truncated terms to identify relevant studies.
OR ‘gut microbiota’ OR ‘gut bacteria’ OR ‘gut dysbiosis’ OR ‘phageome’ OR ‘faecal’ OR ‘faecal microbiota transplant’ OR ‘intestinal microbiota transfer’ OR ‘faeces infusion’ OR ‘donor faeces infusion’)

2. (‘alpha diversity’ OR ‘beta diversity’ OR ‘human’ OR ‘animal’ OR ‘intestine flora’ OR ‘microbial diversity’ OR ‘taxonomy’ OR ‘metagenome’ OR ‘microbiota’ OR ‘gut microbiome composition’ OR ‘metabolomic’ OR ‘compositional alteration’ OR ‘functional alteration’ OR ‘brain function’ OR ‘symptom severity’ OR ‘disease severity’ OR ‘behaviour’ OR ‘functional pathway’)

3. Searches 1 and 2 were then be combined (1 ‘OR’ 2)

4. (‘schizophrenia’ OR ‘psychosis’ OR ‘psychoses’ OR ‘psychotic disorder’ OR ‘schizophrenic disorder’ OR ‘mental illness’ OR ‘mental disease’ OR ‘psychiatric’ OR ‘psychosis’ OR ‘psychiatric disorder’ OR ‘major psychiatric disorder’ OR ‘major psychiatric illness’ OR ‘brief psychotic episode’ OR ‘first episode psychosis’ OR ‘early psychosis’ OR ‘new episode psychosis’ OR ‘new psychosis’)

5. Searches 3 and 4 were then be combined (3 ‘AND’ 4)

The search strategy will be adapted for PsycINFO, EMBASE, Web of Science and Cochrane. Further search terms will be identified via descriptive terms under MeSH terms.

**Selection of studies**

After conducting the initial literature search as described above in the “searches” section, two reviewers (NM and KO) will independently screen titles and abstracts, excluding studies that did not meet the eligibility criteria. Full text of potentially eligible studies will then be obtained and screened by the same reviewers. Any disagreement at this stage will be mediated through a third reviewer (GC). A PRISMA flow chart will display the articles examined at each stage, detailing the number of papers included and excluded and reasons for exclusion (online supplemental appendix 2).

**Data extraction and management**

Two reviewers (NM and SA) will extract the data from included studies using a pre-piloted data collection form in order to meet MECIR standards (online supplemental appendix 3). Any disagreement will be discussed with a third independent reviewer (ASK). The following information will be retrieved:

- General information: Study ID, reference citation, author contact details
- Methods: Aim of study, design, start and end date, duration of participation, ethical approval needed / obtained
- Participants: Population description, setting, inclusion and exclusion criteria, method of recruitment, number of cases, number of controls, withdrawals and exclusions
- Demographics: Age (at time sample was taken), gender, diagnostic tool, subgroups measure / reported
- Compositional and functional outputs and information on how this data was analysed will be retrieved from all included studies. The key conclusions of the study author will be retrieved.

In case of duplicate publication of the same data, we will include the publication with most relevant data to our study question, or with the largest cohort if both are relevant. Where required information is not directly available from the studies, study authors will be contacted to request this information. Study authors will be contacted via email. In the case where no response is given a follow-up reminder email will be sent.

**Outcome data**

Compositional outcomes will include alpha diversity (e.g. Shannon diversity index / Faith’s Phylogenetic Diversity), beta diversity (e.g. Bray-Curtis dissimilarity, Unifrac, Unweighted unifrac), diversity analysis (e.g. PERMANOVA), differential abundance at phylum and genus level and across taxonomic levels (e.g. ANCOM), and associations of compositional alterations with demographic and clinical characteristics of the population.

Functional outcomes will include predicted (16s) or actual (metagenomic) differential abundance of microbial genes, metabolic pathways, hormones, brain volume or function, behavioural changes, associations of functional alterations with demographic and clinical characteristics of the population.

**Risk of bias assessment**

Quality assessment will be carried out using existing appraisal checklists for case-control, cohort or cross-sectional studies provided in the Newcastle-Ottawa Scale. For each study, risk of bias will be classified (high, moderate or low) by two review authors (NM and SA) independently. Data quality for each study will be recorded in a spreadsheet and a table summarising the quality of assessment/evidence. Any disagreement will be discussed with a third reviewer (ASK).

**Data synthesis and statistical analysis**

Systematic Review: Studies will be grouped and analysed according to sequencing approach and key outputs, and tables will display the summary characteristics of all papers included in the systematic review. The tables will outline the following: characteristics of study populations (N, age, sex), diagnostic criteria, study design, intervention/test type, and outcomes. The outcomes refer to the difference in the diversity and composition of oral and gut microbiota between psychosis / schizophrenia groups and non-psychosis / non-schizophrenia groups.

Meta-analysis: When at least two studies reported the same outcome, the reported effect estimates will be pooled using random-effects meta-analyses. Mean difference (MD) and 95% confidence interval (CI) will be calculated, when there are standardised methods in the used scales, to assess alterations in the oral and gut microbiota in patients with psychosis compared to healthy controls. The pooled effect estimates...
will be displayed in a forest plot with 95% CIs. Cohen’s criteria will be used to interpret effect sizes: small (0.2), medium (0.5), and large effects (0.8). The Q and I² statistics will be used to test heterogeneity between studies. The statistical heterogeneity between studies will be assessed according to I² values; 25%, 50% and 75% will be used to indicate a low, moderate and high level of heterogeneity respectively. If high heterogeneity is observed, this will be explored using subgroup analyses. Subgroup analysis will be conducted according to study design and risk of bias assessment, and if the meta-analyses allow such an approach to be undertaken.

If the data allow for meta-analysis, a sensitivity analysis will be conducted, excluding one study at a time to assess whether specific studies have a major influence on the results. Potential publication bias will be assessed by visual inspection of funnel plots, and the asymmetry of the funnel plot will be statistically examined using Egger’s test. All analyses will be performed using Review Manager, version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark) and Stata, version 16 for Egger’s test. P<0.05 will be considered statistically significant.

Ethics
This study is based on published data and will not include any human participants or animals; thus, ethical approval is not required. Results of this study are expected to be published in peer-reviewed journals or conference abstracts.

Discussion
Growing evidence suggests that there are differences in the alpha and beta diversity in the microbial composition of people with psychosis and schizophrenia as compared with controls. A smaller number of studies explore the predicted or actual functional alterations in microbial genes or metabolic pathways associated with these differences. Changes in microbiota composition in psychosis and schizophrenia have been correlated with altered brain structure and function, altered immunity, altered metabolic pathways and symptom severity. Altered metabolic pathways have, in turn, been associated with inflammatory cytokines and risk for coronary heart disease in psychosis and schizophrenia. This has been replicated in animal studies with specific behavioural patterns. Changes in microbiota composition have also been identified as potential biomarkers for psychosis and schizophrenia that might aid in diagnosis. Understanding how predicted or actual functional alterations in microbial genes or metabolic pathways influence symptomatic expression and downstream clinical outcomes may contribute to the development of microbiome targeted interventions for psychosis and schizophrenia.

Our study has limitations. Given the inclusion of observational studies and the anticipated variance in study methodology and design, we anticipate large interstudy heterogeneity. Sources of heterogeneity will be further explored using subgroup analysis and meta-regression. We anticipate the number of included studies will be small. This is likely to be particularly true of those exploring the predicted alterations in functional pathways.

Study status
Preliminary searches, piloting of the study selection process and formal screening of search results against eligibility criteria has been completed. Data extraction, risk of bias (quality) assessment and data analysis is ongoing.

Data availability
Zenodo. Extended data for ‘Compositional and functional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia: A systematic review’.

https://doi.org/10.5281/zenodo.5501952

This project contains the following underlying data:
- Appendix 1: Completed PRISMA-P checklist
- Appendix 2: PRISMA flow diagram for studies of oral and gut microbiome in psychosis or schizophrenia
- Appendix 3: Data collection form

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Contributors
KO is the guarantor of this systematic review, initiated this research and designed the systematic review protocol. NM, AK and GC contributed to the design and revision of the systematic review protocol. NM, KO and GC completed the pilot literature search and the formal selection of studies. NM, SA and AK will conduct the data extraction, evaluation of risk of bias and quantitative synthesis. NM and KO will draft the manuscript. All the authors will be involved in result interpretation. All the authors contributed to the review and revision of the manuscript and approved the publication.

References
1. Szelifowski T, Yun AL, Lennox BR, et al.: The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications. Front Psychiatry. 2020; 11: 156.
2. Sylvia KE, Demas GE: A gut feeling: microbiome-brain-immune interactions modulate social and affective behaviors. Horm Behav. 2018; 99: 41–49.
3. Zhu B, Wang X, Li L: Human gut microbiome: the second genome of human body. Protein Cell. 2010; 1(8): 718–25.
4. Lynch SV, Pedersen O: The human intestinal microbiome in health and disease. N Engl J Med. 2016; 375(24): 2369-2379. PubMed Abstract | Publisher Full Text

5. Dinan TG, Cryan JF: Melancholic microbes: a link between gut microbiota and depression? Neurogastroenterol Motil. 2013; 25(9): 713-9. PubMed Abstract | Publisher Full Text

6. Cryan JF, O'Riordan KJ, Cowan CSM, et al.: The microbiota-gut-brain axis. Physiol Rev. 2019; 99(4): 1877-2013. PubMed Abstract | Publisher Full Text

7. Cryan JF, O'Mahony SM: The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011; 23(3): 187-92. PubMed Abstract | Publisher Full Text

8. Zhu X, Han Y, Du, et al.: Microbiota-gut-brain axis and the central nervous system. NATURE. 2017; 8:329-350. PubMed Abstract | Publisher Full Text | Free Full Text

9. O'Mahony SM, Clarke G, Borre YE, et al.: Serotonin, tryptophan metabolism and the brain microbe-microbiome axis. Behav Brain Res. 2015; 277: 32-48. PubMed Abstract | Publisher Full Text | Free Full Text

10. Rogers GB, Heating DJ, Young RL, et al.: From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016; 21(6): 738-48. PubMed Abstract | Publisher Full Text | Free Full Text

11. Huo R, Zeng B, Zeng L, et al.: Microbiota modulate anxiety-like behavior and endocrine abnormalities in hypothalamic-pituitary-adrenal axis. Front Cell Infect Microbiol. 2017; 7: 489. PubMed Abstract | Publisher Full Text | Free Full Text

12. Waclawikova B, El Ady S: Role of microbiota and tryptophan metabolites in the remodelling of intestinal inflammation on brain and depression. Pharmaceuticuals (Basel). 2018; 11(3): 63. PubMed Abstract | Publisher Full Text | Free Full Text

13. Stefano GB, Pilions N, Piacet R, et al.: Gut, Microbiome, and Brain Regulatory Axis: Relevance to Neurodegenerative and Psychiatric Disorders. Cell Mol Neurobiol. 2018; 38(6): 1197-1206. PubMed Abstract | Publisher Full Text | Free Full Text

14. Zheng P, Zeng B, Zhou C, et al.: Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol Psychiatry. 2016; 21(6): 786-96. PubMed Abstract | Publisher Full Text | Free Full Text

15. Pan S, Clarke G, Berk M, et al.: The gut microbiome and diet in psychiatry: focus on depression. Curr Opin Psychiatry. 2015; 28(1): 1-6. PubMed Abstract | Publisher Full Text | Free Full Text

16. Boertien JM, Pereira PAB, Ate VTE, et al.: Increasing comparability and utility of gut microbiome studies in Parkinson's disease: a systematic review. J Parkinsons Dis. 2019; 9(2): S297-S312. PubMed Abstract | Publisher Full Text | Free Full Text

17. Saumyan V, Margolis KG, Luna RA: Autism spectrum disorder as a brain-gut-microbiome axis disorder. Dig Dis Sci. 2020; 65(3): 818-828. PubMed Abstract | Publisher Full Text | Free Full Text

18. Ming X, Chen N, Ray C, et al.: A gut feeling: a hypothesis of the role of the microbiome in attention-deficit/hyperactivity disorder. Child Neuro N. 2018; 5: 2320048187867997. PubMed Abstract | Publisher Full Text | Free Full Text

19. LeGM, Mostert IC, Zopipka Tadvok W, et al.: The role of the gut-brain axis in attention-deficit/hyperactivity disorder. Gastroenterol Clin North Am. 2019; 48(3): 407-431. PubMed Abstract | Publisher Full Text | Free Full Text

20. Nguyen TT, Kosiolekt, Talaybe, et al.: Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects. Schizophr Res. 2019; 204: 23-29. PubMed Abstract | Publisher Full Text | Free Full Text

21. Schwarz E, Maukonen J, Hyttynen T, et al.: Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response. Schizophr Res. 2018; 192: 398-403. PubMed Abstract | Publisher Full Text | Free Full Text

22. Zhang X, Fan L, Zhang Z, et al.: Analysis of gut microbiota in first episode, drug-naive Chinese patients with schizophrenia: A pilot study. Behav Brain Res. 2020; 379: 112734. PubMed Abstract | Publisher Full Text | Free Full Text

23. Lomo A, Zwickler A: Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness. World Psychiatry. 2017; 16(2): 121-128. PubMed Abstract | Publisher Full Text | Free Full Text

24. Brugger SP, Angelussi I, Abitargh A, et al.: Heterogeneity of striatal dopamine function in schizophrenia: meta-analysis of variance. Bio Psychiatry. 2020; 87(3): 215-224. PubMed Abstract | Publisher Full Text | Free Full Text

25. McCutcheon RA, Pillinger T, Rodgaali M, et al.: Glutamate connectivity associations converge upon the oral and gut microbiota in patients with psychosis or schizophrenia: A systematic review. Zenodo. 2021. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021952

26. Xu M, Von AHL: GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. Acta Pharmacol Sin. 2018; 39(5): 733-753. PubMed Abstract | Publisher Full Text | Free Full Text

27. Nguyen TT, Kosiolekt, Talaybe, et al.: Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder. J Psychiatr Res. 2018; 99: 50-61. PubMed Abstract | Publisher Full Text | Free Full Text

28. Severance EG, Panavudsky E, Castiglione J, et al.: Neurogastroenterology and psychiatry: embracing the reality of poly-peritoneal axis. J Psychiatr Res. 2018; 153(5): 27. PubMed Abstract | Publisher Full Text | Free Full Text

29. Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007; 64(9): 1123-31. PubMed Abstract | Publisher Full Text | Free Full Text

30. Obata Y, Pachnis V: The effect of microbiota and the immune system on the development and organization of the enteric nervous system. Gastroenterology. 2016; 151(5): 836-844. PubMed Abstract | Publisher Full Text | Free Full Text

31. Yaod WW, Yu K, Donaldson GP, et al.: Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015; 161(2): 264-76. PubMed Abstract | Publisher Full Text | Free Full Text

32. Codagorne MG, Spichak S, O'Mahony SM, et al.: Programming bugs: microbiota and the developmental origins of brain health and disease. Biol Psychiatry. 2019; 86(2): 150-62. PubMed Abstract | Publisher Full Text | Free Full Text

33. Dinan TG, Borre YE, Cryan JF: Genomics of schizophrenia: time to consider the gut microbiome? Mol Psychiatry. 2018; 19(12): 1252-7. PubMed Abstract | Publisher Full Text | Free Full Text

34. Moerer D, Sharron L, Clarke EM, et al.: Altered gut microbiota in schizophrenia. Curr Opin Psychiatry. 2020; 33(1): 34-40. PubMed Abstract | Publisher Full Text | Free Full Text

35. Chen SQ, Han D, Ding M, et al.: Identifying psychiatric disorder-associated gut microbiota using microbiota-related gene set enrichment analysis. Brief Bioinform. 2020; 21(3): 987-1003. PubMed Abstract | Publisher Full Text | Free Full Text

36. Li S, Song J, Ke P, et al.: The gut microbiome is associated with brain function and structure in schizophrenia. Sci Rep. 2021; 11(1): 9743. PubMed Abstract | Publisher Full Text | Free Full Text

37. Liang W, Huang Y, Tan X, et al.: Alterations of glycerophospholipid and fatty acyl metabolism in multiple brain regions of schizophrenia microbiota recipient mice. Neuropsychopharmacol. 2019; 15: 3219-3229. PubMed Abstract | Publisher Full Text | Free Full Text

38. Shen Y, Xu J, Li Z, et al.: Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study. Schizophr Res. 2018; 197: 470-477. PubMed Abstract | Publisher Full Text | Free Full Text

39. Xu R, Wu L, Liang J, et al.: Altered gut microbiota and mucosal immunity in patients with schizophrenia. Brain Behav Immun. 2020; 85: 120-7. PubMed Abstract | Publisher Full Text | Free Full Text

40. Pan R, Zhang X, Gao J, et al.: Analysis of the diversity of intestinal microbiota and its potential value as a biomarker in patients with schizophrenia: A cohort study. Psychiatr Res. 2020; 291: 113260. PubMed Abstract | Publisher Full Text | Free Full Text

41. Nguyen TT, Kosiolekt, Talaybe, et al.: Gut microbiota in Schizophrenia: Altered functional pathways related to immune modulation and atherosclerotic risk. Brain Behav Immun. 2021; 91: 245-256. PubMed Abstract | Publisher Full Text | Free Full Text

42. Zhang P, Zeng B, Liu M, et al.: The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv. 2019; 5(2): eaau8317. PubMed Abstract | Publisher Full Text | Free Full Text

43. Zhu F, Guo R, Wang W, et al.: Transplantation of microbiota from drug-free patients with schizophrenia causes schizophrenia-like abnormal behaviors and dysregulated kynurenine metabolism in mice. Mol Psychiatry. 2020; 25(11): 2905-2918. PubMed Abstract | Publisher Full Text | Free Full Text

44. Murray NW, Al Khalaf S, Kahmann D, et al.: Extended data for ‘Compositional and functional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia: A systematic review’. Zenodo. 2021. http://www.ncbi.nlm.nih.gov/pubmed/35051992
The microbiome is an interesting and rapidly growing area of research and its importance for human health is becoming more and more obvious. How the gut microbiome affects the mammalian brain, especially in mental disorders is an area of great interest currently. Different teams using different approaches, both in men and mice have been published in this field. The aim of the current project is to streamline this information, by undertaking a systematic review and meta-analysis of relevant data to further the understanding how changes in microbial genes or metabolic pathways influence symptomatic expression and clinical outcomes. It is hoped that the information gained will aid in development of microbiome targeted interventions for psychosis.

The manuscript study protocol submitted gives a great background to the field and describes the need for a systematic review and meta-analysis. The authors are very clear about their search strategy and have already proven that the keywords used are giving good results. In addition, they have already used the PRISMA template (the golden standard for systematic review) for their search and have screened the articles obtained and funnelled down the list to 21 papers/studies to be included. The hypothesis of their work is well described and the authors seem very realistic about the outcome. To me, this looks very well thought through and I have no doubt that despite the small number of studies included, some good results can be expected that will further the field.

While I am very enthusiastic about the study and the information that will be gained, the authors do propose to include findings from animal studies. Not much information is provided in the manuscript so far but it would be helpful to the reader if the authors state how they are planning to integrate this information and if they anticipate this could cause some problems.

Overall, a very well described manuscript and a study to watch out for.

Is the rationale for, and objectives of, the study clearly described?
Yes

Is the study design appropriate for the research question?
Yes

Are sufficient details of the methods provided to allow replication by others?
Yes

Are the datasets clearly presented in a useable and accessible format?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Psychotic disorders, clinical high risk of psychosis, first episode psychosis, proteomics, biochemistry

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 14 October 2021
https://doi.org/10.21956/hrbopenres.14618.r30530

© 2021 Lennox B et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Monty Lyman
University of Oxford, Oxford, UK
Belinda R. Lennox
Department of Psychiatry, University of Oxford, Oxford, UK

This protocol for a systematic review is detailed, thorough and well placed to answer a clinically relevant and interesting research question. The methods – from assessing risk of bias to statistical analysis – fulfil PRISMA criteria and are clearly described, enabling replication. The search terms strike a good balance of being both broad enough to identify many papers but also targeted enough to be relevant to answering the research question.

We have a few minor suggestions for the authors:

1) The introduction should include clear definitions of both compositional and functional alterations. While these are indirectly described throughout the paper - and fleshed out in the 'Outcome data' section - these should be clearly defined at the start of the paper.

2) In the introduction, it states that ‘psychosis is associated with an array of mental illnesses including schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder and
depression’, however only schizophrenia features in the search strategy. If other disorders such as bipolar disorder are not included, it would be helpful if the rationale for this is explained in the paper.

3) The sentence ‘In fact, gastrointestinal diseases are the third leading cause of natural deaths in schizophrenia’ in the introduction is arguably extraneous to the argument and direction of the paper. The authors of the reference supporting this sentence admit that their paper does not take into account the influence of antipsychotics on gastrointestinal diseases, including GI dysmotility and clozapine-induced bowel obstruction. Perhaps this statement could be omitted?

Aside these minor suggestions to the introduction, we believe that this is an excellent study protocol and we look forward to reading the results on completion of the study.

**Is the rationale for, and objectives of, the study clearly described?**
Yes

**Is the study design appropriate for the research question?**
Yes

**Are sufficient details of the methods provided to allow replication by others?**
Yes

**Are the datasets clearly presented in a usable and accessible format?**
Not applicable

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Academic Clinical Fellow in Psychiatry, University of Oxford. Studying the relationship between the gut microbiome and mental health.

**We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**